This is a working overview of Alpha-MSH, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-31. Anything still debated is marked as such rather than presented as settled.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
=== Japan === Manfred Kiese at the Pharmacological Institute in Berlin published a survey of literature on antibiotics in the 7 August 1943 issue of Klinische Wochenschrift that included the Oxford team's publications. A copy was acquired by the Japanese embassy in Berlin and taken to Japan on the Japanese submarine I-8, which docked at Kure, Hiroshima, on 21 December 1943. The article was translated into Japanese, and production of penicillin was underway by 1 February 1944. By mid-May, a research team under Hamao Umezawa had tested 750 different strains of mould and found that 75 exhibited antibiotic activity. Experiments were conducted on mice to determine efficacy and toxicity. The Morinaga Milk company had a small penicillin production plant in operation in Mishima, Shizuoka, by the end of the year, and the Banyu Pharmaceutical Company opened a small plant in Okazaki, Aichi, in January 1945. The penicillin was called "Hekiso" after its blue colour. By 1948 Japan had become the third country, after the US and UK, to become self-sufficient in penicillin, and exports to China and Korea began the following year.
In early September 2024, Little Caesars announced that it would be exiting Singapore, with the last day of operations for the chain being September 30. The last store was in Funan, after the gradual closure of the chain's six other branches throughout the island. In 2022, Little Caesars had plans to expand into France, Germany, and Portugal. In July 2025, Little Caesars expanded to the United Arab Emirates, opening its first branch in Al Barsha, Dubai In May 2026, Little Caesars expanded to Malaysia, opening its first branch in Damansara Utama.
Australian workers were among the world's wealthiest by the 1980s, but Parliament decided to follow US and UK models to reduce sectoral collective bargaining and awards, believing that it halted "productive innovation". In a 1983 Prices and Incomes Accord between Bob Hawke's Australian Labor Party and the Australian Council of Trade Unions, it was agreed that there should be minimum wage increases across whole sectors, and then further payments if productivity improved at enterprise level. This approach was codified in the Industrial Relations Act 1988, where industry-wide awards only provided a minimum safety net, enterprise bargaining would create certified agreements for higher wages, and unions and employers could take collective action including strikes, if certain conditions were fulfilled. The Industrial Relations Reform Act 1993 added provisions on unfair dismissal, and that non-union workplaces could also make collective agreements, if approved by a special majority, there was "no disadvantage" compared to awards, and workers were adequately informed about the bargain. These Acts relied on the Constitution's trade and commerce, corporations, and external relations powers, rather than the arbitration powers, since the High Court had indicated this was a valid basis for labour laws.
== Awards == 2015 Sundance Film Festival Winner, Special Jury Award for Dramatic Feature: Advantageous Nominee, Grand Jury Prize for Dramatic Feature: Advantageous LA Asian Pacific Film Fest Winner, Editing, score, and directing awards for Advantageous (feature) - 2015 Winner, Golden Reel Award for Excellence in Short Film: Advantageous - 2013 2012 Rhode Island Horror Film Festival Winner, Best Science Fiction Film: Advantageous (Short) Asian American International Film Festival Winner, Best Narrative: Half Life - 2008 Winner, Emerging Director Award for Best Feature: Half Life - 2008 Nominee, Excellence in Short Filmmaking Award: Futurestate - 2013 Austin Fantastic Fest Nominee, Short Film Award: Advantageous (short) - 2012 Cleveland International Film Festival Nominee, Best Women's Short Film: Advantageous (short) - 2013 Nominee, Best Live Action Short Film: Advantageous (short) - 2013 Film Independent Spirit Awards Nominee, John Cassavetes Award: (2016) Shared with Jacqueline Kim, Robert M.
=== Pharmacokinetics === Metabolic studies indicate that protriptyline is well absorbed from the gastrointestinal tract and is rapidly sequestered in tissues. Relatively low plasma levels are found after administration, and only a small amount of unchanged drug is excreted in the urine of dogs and rabbits. Preliminary studies indicate that demethylation of the secondary amine moiety occurs to a significant extent, and that metabolic transformation takes place in the liver. It penetrates the brain rapidly in mice and rats, and moreover that which is present in the brain is almost all unchanged drug. Studies on the disposition of radioactive protriptyline in human test subjects showed significant plasma levels within 2 hours, peaking at 8 to 12 hours, then declining gradually. Urinary excretion studies in the same subjects showed significant amounts of radioactivity in 2 hours. The rate of excretion was slow. Cumulative urinary excretion during 16 days accounted for approximately 50% of the drug. The fecal route of excretion did not seem to be important. Protriptyline has uniquely low dosing among TCAs, likely due to its exceptionally long terminal half-life. It is used in dosages of 15 to 40 mg/day, whereas most other TCAs are used at dosages of 75 to 300 mg/day. The maximum dose is 60 mg/day. Therapeutic levels of protriptyline are typically in the range of 70 to 250 ng/mL (266-950 nmol/L), which is similar to that of other TCAs
Sources: en.wikipedia.org
Additionally, a new research program called ACTINET has been started in the EU to make transmutation possible on an industrial scale. According to U. S. President Bush's Global Nuclear Energy Partnership (GNEP) of 2007, the United States is actively promoting research on transmutation technologies needed to markedly reduce the problem of nuclear waste treatment. There have also been theoretical studies involving the use of fusion reactors as so-called "actinide burners" where a fusion reactor plasma such as in a tokamak, could be "doped" with a small amount of the "minor" transuranic atoms which would be transmuted (meaning fissioned in the actinide case) to lighter elements upon their successive bombardment by the very high energy neutrons produced by the fusion of deuterium and tritium in the reactor. A study at MIT found that only two or three fusion reactors with parameters similar to that of the International Thermonuclear Experimental Reactor (ITER) could transmute the entire annual minor actinide production from all of the light-water reactors presently operating in the United States fleet while simultaneously generating approximately one gigawatt of power from each reactor. Opportunities for managing nuclear waste by transmutation are also being explored in linear particle accelerators.
Pituitary adenylate cyclase-activating polypeptide type 1 receptor InterPro: IPR002285 PACAPR (ADCYAP1R1) Calcitonin receptor InterPro: IPR003287 CALCR Calcitonin receptor-like receptor InterPro: IPR015476 CALCRL Corticotropin-releasing hormone receptor InterPro: IPR003051 CRHR1; CRHR2 Glucose-dependent insulinotropic polypeptide receptor/Gastric inhibitory polypeptide receptor InterPro: IPR001749 GIPR Glucagon receptor InterPro: IPR003291 GCGR Glucagon receptor-related InterPro: IPR003290 GLP1R; GLP2R; Growth hormone releasing hormone receptor InterPro: IPR003288 GHRHR Parathyroid hormone receptor InterPro: IPR002170 PTHR1; PTHR2 Secretin receptor InterPro: IPR002144 SCTR Vasoactive intestinal peptide receptor InterPro: IPR001571 VIPR1; VIPR2
With the presentation of Tiberius as the figure responsible for the retrieval of the standards in the breastplate’s imagery, he would have associated himself in the minds of viewers with the deified emperor and suggested continuity between their reigns, as Augustus himself had done previously with his own deified adoptive father Julius Caesar (though Caesar was not himself an emperor). Under this hypothesis, the dating of the statue can be placed during the first years of Tiberius' reign as emperor (AD 14 — AD 37). However, it is also possible that it was commissioned by Livia herself, Augustus's wife at the time of his death.
Dihydrowogonin is a natural product, which as a flavonoid belongs to the flavanone subclass. It has a flavan backbone with a hydroxyl and methoxy functional groups. It possesses some antioxidant, anti-inflammatory, and neuroprotective properties. Dihydrowogonin has been identified as a major constituent in the methanol extract of the species, Prunus avium (wild cherry), mostly in the bark. Dihydrowogonin appears to exhibit antimicrobial and antibiofilm behaviour, particularly against the Gram-positive bacteria like Staphylococcus aureus. In addition, it can interact with glutathione transferases in white-rot fungi; thus, this suggests a role in the detoxification processes during wood degradation. It has been studied for potential applications in pharmacology, particularly as an antimicrobial and antioxidant agent, and in neuroprotective therapies.
Sources: en.wikipedia.org
Reception to the advertisement was mixed, as some social media users thought its mention of genetics evoked eugenicist ideas. The Dunkin' campaign launched less than a week after American Eagle launched its campaign "Sydney Sweeney Has Great Jeans", which led to similar backlash. On February 8, 2026, during Super Bowl LX, Ben Affleck appeared in a commercial that parodies Good Will Hunting, a film that Affleck co-wrote and starred in, as a 1990s sitcom. He portrays "Will Dunkin'" a parody of Damon's character, "Will Hunting", where he's cast alongside 1990s sitcom stars such as Jason Alexander, Jennifer Aniston, Jasmine Guy, Alfonso Ribeiro, Matt LeBlanc, and Jaleel White. Tom Brady also appears in the commercial.
For their launch into space, there is today an unused superpower rocket, Energia, which is the most powerful in the world. In the late 1980s, the Soviet Union built the Mir orbital station. It was built on the construction of Salyut stations and its only role was civilian-grade research tasks. Mir was the only orbital station in operation from 1986 to 1998. Gradually, other modules were added to it, including American modules. However, the station deteriorated rapidly after a fire on board and was deorbited in 2001, burning up in the Earth's atmosphere.
A cancer-associated fibroblast (CAF) (also known as tumour-associated fibroblast; carcinogenic-associated fibroblast; activated fibroblast) is a cell type within the tumor microenvironment that promotes tumorigenic features by initiating the remodelling of the extracellular matrix or by secreting cytokines. CAFs are a complex and abundant cell type within the tumour microenvironment; the number cannot decrease, as they are unable to undergo apoptosis. CAFs have been found to be abundant in a tumour stroma. Myofibroblasts and fibroblasts make up CAFs. The functions of these CAFs have been known to stimulate angiogenesis, supporting the formation of tumours and thus proliferation of cancer cell and metastasis. Cancer cells are usually also drug resistant, which is contributed by CAFs. As such, this interaction is being studied for potential anti-cancer therapy. Normal fibroblasts aid in the production of components of the extracellular matrix such as collagens, fibres, glycosaminoglycans and glycoproteins and are therefore vital in tissue repair in wound healing. CAFs however, are derived from either normal fibroblasts, pericytes, smooth muscle cells, fibrocytes or mesenchymal stem cells These CAFs then go on to support tumour growth by secreting growth factors such as Vascular Endothelial Growth Factor (VEGF), Platelet Derived Growth Factor (PDGF) and Fibroblast Growth Factor (FGF) and other chemokines to stimulate angiogenesis and thus the growth of a tumour.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.